Severe progressive scarring pembrolizumab‐induced lichen planopilaris in a patient with metastatic melanoma
Aarthy Uthayakumar, Emily Rudd, Mariana Noy, Justin Weir, James Larkin, Louise Fearfield
Abstract
Lichenoid reactions are one of the many cutaneous immune-related adverse events seen with the use of immune checkpoint inhibitors, particularly anti-PD1 inhibitors. We present a rare care of severe lichen planopilaris secondary to pembrolizumab, with progression even after cessation of immunotherapy. It is important to recognise the significant long-term impact of these cutaneous adverse effects on patient's quality of life.
Topics & Concepts
MedicinePembrolizumabDermatologyAdverse effectMetastatic melanomaImmunotherapyQuality of life (healthcare)MelanomaLichen sclerosusOncologyInternal medicineCancerCancer researchNursingCancer Immunotherapy and BiomarkersColorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways